ChemComm

Accepted Manuscript



ROYAL SOCIETY OF CHEMISTRY

www.rsc.org/chemcomm

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

A specific fluorescent probe for NO based on a new NO binding group

Xin Lv,[a] Yue Wang,[a] Song Zhang,[b] Yawei Liu,[a] Jian Zhang,[a] and Wei Guo*,[a]

Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX
DOI: 10.1039/b000000x

By incorporation of a specific NO-binding group 2-amino-3'-dimethylaminobiphenyl into Bodipy dye, fluorescent probe 1 was constructed, which exhibited high selectivity for NO over other ROS/RNS as well as DHA, AA and MGO.

Nitric oxide (NO), produced by nitric oxide synthases, has been regarded as a ubiquitous signaling molecule, and plays key roles in various physiological as well as pathological processes. Endogenous NO has mediated multiple processes in the various physiological systems, such as the cardiovascular system, immune system, and the central and peripheral nervous system.[1] Also, studies have shown that its deregulation has been correlated with the symptoms of cancer, endothelial dysfunction, and neurodegenerative diseases.[2] However, the mechanisms by which it performs its diverse biological roles still remain elusive. Therefore, an efficient method for sensitively and selectively probing NO in biological systems is highly required for better understanding of its origins, activities, and biological functions.

Due to its simplicity, sensitivity, real-time imaging, especially nondestructive detection, fluorescence techniques combined with microscopy have been regarded as a powerful tool for sensing and imaging targeted biomolecules in live cells or tissues. Given this, a number of fluorescent NO probes have been reported to date[3] by exploiting the specific reactions of NO with *o*-phenylenediamino (OPD) moiety,[4,5] metal–ligand complexes,[6] and others.[7] Among these methods, OPD-based fluorescent probes, pioneered by Nagano's group, have shown the immense potential to visualize NO *in vitro* and *in vivo*.[4,5] Moreover, some of them are commercially available,[8] and have greatly promoted NO-related biological investigation. The corresponding sensing mechanism is based on the irreversible reaction of the OPD group with NO^+ or N_2O_3 to give benzotriazole derivatives, by which the *off-on* fluorescence response is achieved through suppression of the photoinduced electron transfer (PET) process. Although in some cases they can provide useful information, the basic chemical problems still remain. First, dehydroascorbic acid (DHA) and ascorbic acid (AA) (micromolar to millimolar levels in many cells[9]) were reported to be able to condense with OPD group to turn on the fluorescence of such probes.[10] Second, it was recently reported that a OPD-based Bodipy fluorescent probe could also detect methylglyoxal (MGO),[11] a dicarbonyl metabolite produced by all living cells, under physiological conditions.[12] Third, benzotriazoles are pH-sensitive, and its deprotonation at physiological pH results in an electron-rich triazolate, which may induces the undesirable fluorescence quenching through PET mechanism to lower the NO detection sensitivity.[4d,f] Therefore, further efforts to overcome these limitations are highly required.

In 2010, Anslyn et al exploited a 2-dimethlyaminophenyl-5-cyano-α-naphthylamine fluorescent probe for NO (Fig. 1A).[13] The probe itself was nonfluorescent, but displayed the obvious fluorescence *off-on* response upon NO treatment due to the NO-triggered formation of a new fluorophore. Notably, the probe displayed excellent selectivity for NO over other reactive oxygen/nitrogen species (ROS/RNS) as well as DHA, and thus appears to be more advantageous than the conventional OPD-based ones from the viewpoint of selectivity. To extend the method to a versatile design platform, in this work we present its a modified version for constructing fluorescent NO probe through integration of a NO-binding group, 2-amino-3'-dimethylaminobiphenyl (**AD**), and a selected fluorophore (Fig. 1B). We think that the strategy may be more useful for the future design of fluorescent NO probes.



Fig. 1 The design strategies for fluorescent NO probes.

As a proof of concept, we designed probe **1** by attachment of the NO-binding group **AD** into the widely used Bodipy dye[14] (Fig. 2). In fact, **AD** functions not only as a NO-binding group, but also as a fluorescence quencher *via* PET to ensure the low background fluorescence. We reasoned that probe **1** is weakly fluorescent due to the PET process from the electron-rich **AD** group to the excited Bodipy fluorophore. Upon treatment with NO, a diazo product **2** was expected to produce based on the reaction mechanism proposed by Anslyn.[13] Due to the absence of the electron-donating amino group in **2**, the above-mentioned PET process would be inhibited, thereby leading to the fluorescence turn-on of the Bodipy fluorophore.



Fig. 2 Proposed sensing mechanism of probe **1** with NO.

Probe **1** was synthesized according the route outlined in Scheme 1. To anchor **AD** group to Bodipy core, the commercially available 4-bromo-3-nitro-benzaldehyde **5** was used as starting material. By use of the standard Bodipy synthetic procedures, intermediate **4** could be easily obtained. Suzuki coupling of **4** with 3-dimethylaminophenylboronic acid gave intermediate **3**. The subsequent reduction of **3** with $SnCl_2$ gave probe **1**. The detailed experimental procedure and characterization data are provided in Supporting Information.



Scheme 1. Synthesis of **1**. (1) (i) 2,4-dimethyl-pyrrole, TFA; (ii) DDQ; (iii) Et_3N, BF_3-Et_2O. (2) 3-dimethylaminophenylboronic acid, $Pd(PPh_3)_4$, K_2CO_3. (3) $SnCl_2$, conc. HCl.

With probe **1** in hand, we first tested the reaction of **1** with NO in EtOH-PBS buffer (20 mM, pH 7.4, 1:1, v/v) at 37 °C by HRMS. DEA•NONOate was used as the source of NO, which is commercially available with half time of 16 min. The free probe **1** exhibited a main peak at *m/z* 459.2565 (Fig. 3A), corresponding to $[\mathbf{1}+H^+]^+$ (*m/z*, calcd: 459.2532). However, after incubation of the probe with excess of DEA•NONOate, a new peak at *m/z* 470.2338 was observed (Fig. 3B), which could be assigned to $[\mathbf{2}+H^+]^+$ (*m/z*, calcd: 470.2328). Moreover, the reaction also elicited an obvious fluorescence turn-on response from a dark background (Fig. 3, inset). The preliminary results are in accordance with our proposed sensing mechanism.



Fig 3 HRMS charts of probe **1** in the absence (A) and presence (B) of the excess of DEA•NONOate in EtOH-PBS buffer (20 mM, pH 7.4, 1:1, v/v). Inset: fluorescent images of probe **1** in the absence (A) and presence (B) of the excess of DEA•NONOate in the same buffer.

Next, we performed the time-dependent fluorescence spectra studies of probe **1** treated with the different concentration of DEA•NONOate in EtOH-PBS buffer (20 mM, pH 7.4, 1:1, v/v). The obtained results indicated that the reaction could be completed within 30 min (Fig. 4A). With a time point of 30 min after addition of DEA·NONOate, we performed the fluorescence titration studies of **1** for NO. As shown in Fig. 4B, probe **1** exhibited a weak emission at 518 nm due to PET from the aniline unit to the excited Bodipy fluorophore. Treatment with DEA•NONOate elicited the obvious enhancement. The changes in the emission intensities became less obvious when the amount of DEA•NONOate is more than 75 μM. In this case, an approximately 5-fold fluorescence enhancement was observed. Moreover, the fluorescence intensities of **1** at 518 nm showed a good linear relationship with DEA•NONOate concentrations from 0 to 15 μM (Fig. 4B, inset), and the detection limit was estimated to be 30 nM based on *S/N* = 3. Thus, probe **1** is potentially useful for monitoring NO in living cells.



Fig. 4 Time-dependent fluorescence intensity changes of **1** (5 μM) upon addition of varied concentrations of DEA•NONOate in. (A) Fluorescence spectra of probe **1** (5 μM) upon addition of DEA•NONOate (0–75 μM) recorded after 30 min. Condition: EtOH-PBS buffer (20 mM, pH 7.4, 1:1, v/v); 37 °C; λ_{ex} = 480 nm; λ_{em} = 518 nm; slits: 5/5 nm.

Further, we evaluated the specificity of probe **1** for NO. We screened a wide array of possible competitive species, including H_2O_2, ClO^-, •OH, O_2^-, $^1O_2$, $ONOO^-$, NO_2^-, NO_3^-, DHA, AA, and MGO, all of which are biologically related (Fig. 5A). In fact, probe **1** was inert to most of these ROS and RNS, and only $^1O_2$ and $ONOO^-$ elicited the minor fluorescence enhancement of 1.4- and 1.5-fold, respecitvely. Notably, probe **1** did not show any response to DHA, AA, and MGO. By comparison, only NO could elicited a big increase of 5-fold in the fluorescence intensity at 518 nm, suggesting the high selectivity of probe **1** toward NO. We attributed the high selectivity of **1** toward NO over DHA, AA, and MGO to the **AD** group in **1**, which fails to condense with the 1,2-dicarbonyl group of DHA/AA/MGO to form quinoxaline heterocycles.



Fig. 5 (A) Fluorescence spectra of **1** (5 μM) treated with various species (10 equiv for NO, $ONOO^-$ and $^1O_2$; 100 equiv for H_2O_2, ClO^-, •OH, O_2^-, NO_2^-, NO_3^-, DHA, AA, and MGO) in EtOH-PBS buffer (20 mM, pH 7.4,

1:1, v/v). (B) Effects of pH on the fluorescence intensity of **1** (5 μM) in the absence (■) or presence (●) of DEA•NONOate (10 equiv). λ_{ex} = 480 nm, λ_{em} = 518 nm, slits: 5/5 nm.

Also, we studied the emission behaves of **1** treated with DEA·NONOate in the different pH environment. As shown in Fig. 5B, probe **1** showed a stable and weak emission in the pH region of 4.5–8.0, and displayed the best response for NO in the pH region of 4.5–7.5. Thus, probe **1** can function well in physiological condition. However, in alkaline condition, the fluorescence enhancement was inhibited, likely due to the fact that DEA•NONOate generates NO in a pH-dependent manner, and is more stable at high pH environment.

Encouraged by the above results, we evaluated the capability of **1** to selectively sense NO in cellular environment. HL-7702 cells (human liver cells) showed no fluorescence in the green channel (Fig. 6A). After incubated with **1** (5 μM) in culture medium for 1 h at 37 °C, HL-7702 cells showed a very weak fluorescence (Fig. 6B), indicating that **1** is cell-permeable. However, strong fluorescence in the cells was observed after the cells were pretreated with **1** for 1 h and further incubated with DEA•NONOate (50 μM) for 1 h (Fig. 6C). These preliminary results confirmed that probe **1** has the potential to visualize NO levels in living cells.



Fig. 6 Fluorescent images of NO in HL-7702 cells using probe **1** (5 μM) at 37 °C. (A) HL-7702 cells. (B) HL-7702 cells incubated with **1** for 1 h. (C) HL-7702 cells pretreated with **1** for 1 h and then incubated with DEA•NONOate (50 μM) for 1 h. (D-F) The corresponding bright-field images. Scale bar: 200 μm.

In summary, we have presented a novel fluorescent probe for NO by incorporation of a new NO-binding group 2-amino-3'-dimethylaminobiphenyl into Bodipy dye. The probe can selectively sense NO over ROS/RNS as well as AA/DHA/MGO with a detection limit as low as 30 nM. The preliminary cell imaging experiments indicate its potential to probe NO chemistry in biological systems.

We acknowledge the National Natural Science Foundation of China (NOs. 21302114 and 21172137) and Scientific and Technological Innovation Programs of Higher Education Institutions in Shanxi for support of this work.

Notes and references

[a]*School of Chemistry and Chemical Engineering, Shanxi University, Taiyuan 030006, China. E-mail: guow@sxu.edu.cn.*
[b]*Shanxi Academy of Analytical Sciences*

† Electronic Supplementary Information (ESI) available: Experimental procedures, supplemental spectra, and the ^{1}H–, ^{13}C– NMR, and MS spectrum. See DOI: 10.1039/b000000x/

1 (a) S. H. Snyder, *Science*, 1992, **257**, 494. (b) S. Jasid, M. Simontacchi, C. G. Bartoli, S. Puntarulo, *Plant Physiol.*, 2006, **142**, 1246. (c) D. Fukumura, S. Kashiwagi, R. K. Jain, *Nat. Rev. Cancer* 2006, **6**, 521.

2 (a) S. Taysi, C. Uslu, F. Akcay, M. Y. Sutbeyaz, *Surg. Today*, 2003, **33**, 651. (b) C. S. Cobbs, J. E. Brenman, K. D. Aldape, D. S. Bredt, M. A. Israel, *Cancer Res.*, 1995, **55**, 727. (c) G. P. Biro, *Current Drug Discovery Technol.*, 2012, **9**, 194. (d) R. J. Giedt, C. J. Yang, J. L. Zweier, A. Matzavinos, B. R. Alevriadou, *Free Radic. Biol. Med.*, 2012, **52**, 348. (e) D. Y. Choi, Y. J. Lee, J. T. Hong, H. J. Lee, *Brain Res. Bull.*, 2012, **87**, 144. (f) M. Gutowicz, *Postep Hig Med Dosw*, 2011, *65*, 104. (g) J. T. Coyle, P. Puttfarcken, *Science*, 1993, **262**, 689.

3 X. Chen, X. Tian, I. Shin, J. Yoon, *Chem. Soc. Rev.*, 2011, **40**, 4783.

4 (a) H. Kojima, K. Sakurai, K. Kikuchi, S. Kawahara, Y. Kirino, H. Nagoshi, Y. Hirata, T. Akaike, H. Maeda, T. Nagano, *Biol. Pharm. Bull.*, 1997, **20**, 1229. (b) H. Kojima, N. Nakatsubo, K. Kikuchi, S. Kawahara, Y. Kirino, H. Nagoshi, Y. Hirata, T. Nagano, *Anal. Chem.*, 1998, **70**, 2446. (c) H. Kojima, Y. Urano, K. Kikuchi, T. Higuchi, Y. Hirata, T. Nagano, *Angew. Chem. Int. Ed.*, 1999, **38**, 21. (d) H. Kojima, M. Hirotani, Y. Urano, K. Kikuchi, T. Higuchi, T. Nagano, *Tetrahedron Lett.*, 2000, **41**, 69. (e) H. Kojima, M. Hirotani, N. Nakatsubo, K. Kikuchi, Y. Urano, T. Higuchi, Y. Hirata, T. Nagano, *Anal. Chem.*, 2001, **73**, 1967. (f) Y. Gabe, Y. Urano, K. Kikuchi, H. Kojima, T. Nagano, *J. Am. Chem. Soc.*, 2004, **126**, 3357. (g) E. Sasaki, H. Kojima, H. Nishimatsu, Y. Urano, K. Kikuchi, Y. Hirata, T. Nagano, *J. Am. Chem. Soc.*, 2005, **127**, 3684. (h) T. Terai, Y. Urano, S. Izumi, H. Hojima, T. Nagano, *Chem. Commun.*, 2012, **48**, 2840.

5 (a) H. Zheng, G.-Q. Shang, S.-Y. Yang, X. Gao, J.-G. Xu, *Org. Lett.*, 2008, **10**, 2357. (b) L. Yuan, W. Lin, Y. Xie, B. Chen, S. Zhu, *J. Am. Chem. Soc.*, 2012, **134**, 1305. (c) H. Yu, Y. Xiao, L. Jin, *J. Am. Chem. Soc.*, 2012, **134**, 17486. (d) H. Yu, X. Zhang, Y. Xiao, W. Zou, L. Wang, L. Jin, *Anal. Chem.*, 2013, **85**, 7076. (e) G. K. Vegesna, S. R. Sripathi, J. Zhang, S. Zhu, W. He, F.-T. Luo, W. J. Jahng, M. Frost, H. Liu, *ACS Appl. Mater. Interfaces*, 2013, **5**, 4107. (f) C. Yu, Y. Wu, F. Zeng, S. Wu, *J. Mater. Chem. B*, 2013, **1**, 4152.

6 (a) M. H. Lim, S. J. Lippard, *J. Am. Chem. Soc.*, 2005, **127**, 12170. (b) R. C. Smith, A. G. Tennyson, M. L. Lim, S. J. Lippard, *Org. Lett.*, 2005, **7**, 3573. (c) M. H. Lim, D. Xu, S. J. Lippard, *Nat. Chem. Biol.*, 2006, **2**, 373. (d) M. H. Lim, B. A. Wong, W. H., Jr. Pitcock, D. Mokshagundam, M.-H. Baik, S. J. Lippard, *J. Am. Chem. Soc.*, 2006, **128**, 4363. (e) M. D. Pluth, L. E. McQuade, S. J. Lippard, *Org. Lett.*, 2010, **12**, 2318. (f) L. E. McQuade, J. Ma, G. Lowe, A. Ghatpande, A. Gelperin, S. J. Lippard, *Proc. Natl. Acad. Sci. USA*, 2010, **107**, 8525. (g) M. D. Pluth, M. R. Chan, L. E. McQuade, S. J. Lippard, *Inorg. Chem.*, 2011, **50**, 9385. (h) X. Hu, J. Wang, X. Zhu, D. Dong, X. Zhang, S. Wu, C. Duan, *Chem. Commun.*, 2011, **47**, 11507.

7 (a) C. Sun, W. Shi, Y. Song, W. Chen, H. Ma, *Chem. Commun.*, 2011, **47**, 8638. (b) T.-W. Shiue, Y.-H. Chen, C.-M. Wu, G. Singh, H.-Y. Chen, C.-H. Hung, W.-F. Liaw, Y.-M. Wang, *Inorg. Chem.*, 2012, **51**, 5400.

8 I. Johnson, and M. T. Z. Spence, *The Molecular Probes Handbook—A Guide to Fluorescent Probes and Labeling Technologies*, Life Technologies, Carlsbad, Calif, USA, 11th edition, 2010.

9 (a) R. A. Grunewald, *Brain Res. Rev.*, 1993, **18**, 123. (b) P. W. Washko, Y. H. Wang, M. Levine, *J. Biol. Chem.*, 1993, **268**, 15531. (c) A. Ek, K. Strom, I. A. Cotgreave, *Biochem. Pharmacol.*, 1995, **50**, 1339. (d) M. E. Rice, I. Russo-Menna, *Neuroscience*, 1998, **82**, 1213.

10 (a) X. Ye, S. S. Rubakhin, J. V. Sweedler, *J. Neurosci. Methods*, 2008, **168**, 373. (b) X. Zhang, W.-S. Kim, N. Hatcher, K. Potgieter, L. L. Moroz, R. Gillette, J. V. Sweedler, *J. Biol. Chem.*, 2002, **277**, 48472.

11 T. Wang, E. F., Jr. Douglass, K. J. Fitzgerald, D. A. Spiegel, *J. Am. Chem. Soc.*, 2013, **135**, 12429.

12 (a) M. P. Kalapos, *Toxicol. Lett.*, 1999, **110**, 145. (b) P. I. Thornalley, *Drug Metab. Drug Interact.*, 2008, **23**, 125.

13 Y. Yang, S. K. Seidlits, M. M. Adams, V. M. Lynch, C. E. Schmidt, E. V. Anslyn, J. B. Shear, *J. Am. Soc. Chem.*, 2010, **132**, 13114.

14 (a) G. Ulrich, R. Ziessel, and A. Harriman, *Angew. Chem. Int. Ed.*, 2008, **47**, 1184. (b) A. Loudet, and K. Burgess, *Chem. Rev.*, 2007, **107**, 4891. (c) N. Boens, V. Leen, W. Dehaen, *Chem. Soc. Rev.*, 2012, **41**, 1130.